An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.

MLA

Lohse, Stefan, et al. “An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.” Cancer Research, vol. 76, no. 2, Jan. 2016, pp. 403–17. EBSCOhost, https://doi.org/10.1158/0008-5472.CAN-15-1232.

APA

Lohse, S., Meyer, S., Meulenbroek, L. A. P. M., Jansen, J. H. M., Nederend, M., Kretschmer, A., Klausz, K., Möginger, U., Derer, S., Rösner, T., Kellner, C., Schewe, D., Sondermann, P., Tiwari, S., Kolarich, D., Peipp, M., Leusen, J. H. W., & Valerius, T. (2016). An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo. Cancer Research, 76(2), 403–417. https://doi.org/10.1158/0008-5472.CAN-15-1232

Chicago

Lohse, Stefan, Saskia Meyer, Laura A P M Meulenbroek, J H Marco Jansen, Maaike Nederend, Anna Kretschmer, Katja Klausz, et al. 2016. “An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.” Cancer Research 76 (2): 403–17. doi:10.1158/0008-5472.CAN-15-1232.